Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04173026 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 21, 2019
Last Update Posted : May 19, 2023
|
Sponsor:
University of Alabama at Birmingham
Information provided by (Responsible Party):
Julie Kanter, University of Alabama at Birmingham
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) study is a multi-center, national, National Heart, Lung and Blood Institute (NHLBI)-funded grant to look at the real-world implementation of stroke prevention guidelines (STOP Protocol) in which transcranial Doppler (TCD), a measure of cerebral blood vessel velocity, is used to screen for stroke risk in children ages 2-16 with sickle cell anemia (SCA). Part 3 of the DISPLACE study is an implementation clinical trial designed to test novel implementation strategies with the goal of improving adherence and implementation of stroke screening. 16 of the lowest scoring implementation rates from DISPLACE Part 1 will participate in DISPLACE Part 3. All original 28 sites from DISPLACE Parts 1 and 2 will receive a patient and provider educational intervention including a re-branding of the TCD as "Sickle Stroke Screen" with a new infographic and educational materials. The 16 sites with moving to Part 3 will be provided a Provider reminder strategy, which is a web based application designed to remind providers of when patients are due for their Sickle Stroke Screen. These 16 sites will be randomized and 8 will be given an additional Patient Communication Strategy. These sites will have a single designed coordinator with whom patients will communicate with about scheduling, rescheduling, and any other questions regarding their Sickle Stroke Screen. Upon completion, data will be analyzed to compare those who have had TCD screenings done appropriately and those who did not as well as the overall effect of the multi level interventions on the changes in TCD rates.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Sickle Cell Disease | Other: Provider-level intervention Other: Patient-level intervention | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 16 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | Randomized cluster controlled implementation study |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) Part 3 |
| Actual Study Start Date : | June 4, 2020 |
| Actual Primary Completion Date : | February 1, 2023 |
| Estimated Study Completion Date : | June 30, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Sickle cell disease
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Provider intervention
A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates.
|
Other: Provider-level intervention
Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
Other Name: Provider Minder |
|
Active Comparator: Provider and Patient level intervention
A web-based application called ProviderMinder has been developed and will be used to alert providers when a patient who has been lost-to-follow-up or has missed their Sickle Stroke Screen (TCD). This will allow providers to follow up with such patients and improve screening rates. Additionally, sites will have a patient intervention of a single Sickle Stroke Screen coordinator who will interact directly with patients to schedule, reschedule, remind, and follow-up on stroke screening. This person will also act as a point of contact for any educational needs the patient may have. The second patient intervention will include the caregivers own mobile device. When Sickle Stroke Screens are scheduled the coordinator will ensure these appointments are directly put into the caregiver's mobile device calendar acting as an additional reminder for stroke screening.
|
Other: Provider-level intervention
Provider minder is a provider-based scheduling and reminder system for stroke screening in SCD
Other Name: Provider Minder Other: Patient-level intervention 50% of centers are randomized to a single stroke screen coordinator as the point of contact for sickle stroke screen
Other Name: Single Coordinator |
Primary Outcome Measures :
- 1. Change in uptake and use of the stroke prevention guidelines (STOP Protocol) as defined in the NHLBI (National Heart, Lung, and Blood Institute) 2014 Sickle Cell Disease (SCD) Guidelines by assessing stroke risk with yearly TCD screens [ Time Frame: baseline-2 years ]The TCD measures the speed of blood flow in the blood vessels of the brain. Any unusually slow of fast speed may indicate a child is at a higher risk for stroke. By ensuring patients receive a yearly TCD more children will get a proper intervention and ideally prevent stroke.
- 2. Change in uptake and use of the stroke prevention guidelines (STOP Protocol) as defined in the NHLBI 2014 SCD Guidelines by implementing chronic red cell transfusion (CRCT) in patients noted to have abnormal TCD screens. [ Time Frame: baseline-2 years ]CRCT has been shown to severely decrease the incidence of stroke in patients who have had TCD screenings with an abnormal result.
- Change in uptake and use of the stroke prevention guidelines (STOP Protocol) as defined in the NHLBI (National Heart, Lung, and Blood Institute) 2014 SCD (Sickle Cell Disease) Guidelines by re-screening patients with conditional TCD screens [ Time Frame: baseline-2 years ]Patients who have a condition TCD are considered to of slightly higher risk than patients with a normal TCD. By re-screening these patients in a shorter time period, providers are able to confirm or reject the initial screening and make the best plan for stroke prevention depending on these outcomes.
- A difference in uptake and use of the stroke prevention guidelines (STOP Protocol) as defined in the NHLBI 2014 SCD Guidelines between between implementation arms measured by assessing yearly TCD screening rates. [ Time Frame: baseline-2 years ]Any difference in TCD implementation rates between each intervention arms will help determine optimal implementation procedures.
Secondary Outcome Measures :
- Barriers to obtaining TCD screening [ Time Frame: baseline-2 years ]Participating sites will carry out key informant interviews with patients/caregivers and stakeholders will be analyzed using content analysis to identify themes pertaining to barriers to obtaining TCD screening, as well as overall perceptions of the intervention(s), barriers to implementing the intervention(s) and satisfaction with the intervention(s).
- Enablers to obtaining TCD screening [ Time Frame: baseline - 2 years ]Participating sites will carry out key informant interviews with patients/caregivers and stakeholders will be analyzed using content analysis to identify themes pertaining to enablers to obtaining TCD screening, as well as overall perceptions of the intervention(s), enablers to implementing the intervention(s) and satisfaction with the intervention(s).
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 2 Years to 7 Years (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Patients with sickle cell anemia (SCA) identified at each institution through International Classification of Diseases 9/10 (ICD-9/ICD-10) codes and local patient databases.
- Patients must have been seen by the designated institution (documented in medical record) a minimum of two times in the either inpatient or outpatient setting at the institution between the years of 01/01/2018-12/31/2019.
- Patients identified will include those currently aged 2-7. Thus children born from 2012 and onward.
- Patients already receiving primary or secondary stroke prevention therapy with CRCT will be included in registration in Web Data Coordination Unit (WEBDCU) but not included in PROVIDER MINDER as they do not require ongoing TCD/SICKLE STROKE SCREEN based on protocol.
Exclusion Criteria:
- Patients who do not have SCA
- Patients who were born before 2012 and therefore do not meet age criteria.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04173026
Locations
| United States, Arkansas | |
| Arkansas Children's Research Institute | |
| Little Rock, Arkansas, United States, 72202 | |
| United States, California | |
| UCSF Benioff Children's Hospital Oakland | |
| Oakland, California, United States, 94609 | |
| United States, Delaware | |
| Nemours Center for Cancer & Blood Disorders | |
| Wilmington, Delaware, United States, 19803 | |
| United States, District of Columbia | |
| Children's National Medical Center | |
| Washington, District of Columbia, United States, 20010 | |
| Howard University Hospital | |
| Washington, District of Columbia, United States, 20060 | |
| United States, Florida | |
| Broward Health Medical Center | |
| Fort Lauderdale, Florida, United States, 33316 | |
| University of Florida Health Shands Children's Hospital | |
| Gainesville, Florida, United States, 32608 | |
| University of Miami | |
| Miami, Florida, United States, 33136 | |
| United States, Georgia | |
| Children's Heathcare of Atlanta | |
| Atlanta, Georgia, United States, 30322 | |
| United States, Illinois | |
| University of Illinois at Chicago | |
| Chicago, Illinois, United States, 60607 | |
| United States, Missouri | |
| SSM Health Cardinal Glennon Children's Hospital | |
| Saint Louis, Missouri, United States, 63104 | |
| St. Louis Children's Hospital | |
| Saint Louis, Missouri, United States, 63110 | |
| United States, New York | |
| Columbia University Medical Center | |
| New York, New York, United States, 10032 | |
| United States, North Carolina | |
| Vidant Medical Center | |
| Greenville, North Carolina, United States, 27834 | |
| United States, Tennessee | |
| Vanderbilt Children's Hospital | |
| Nashville, Tennessee, United States, 37232 | |
Sponsors and Collaborators
University of Alabama at Birmingham
Investigators
| Principal Investigator: | Julie Kanter, MD | University of Alabama at Birmingham |
| Responsible Party: | Julie Kanter, Principal Investigator, University of Alabama at Birmingham |
| ClinicalTrials.gov Identifier: | NCT04173026 |
| Other Study ID Numbers: |
NIH 5R01HL133896-02 |
| First Posted: | November 21, 2019 Key Record Dates |
| Last Update Posted: | May 19, 2023 |
| Last Verified: | May 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | To be determined. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Anemia, Sickle Cell Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia |
Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn |